CardioVascular BioTherapeutics Engages the Bruckner Group To Find a Joint Commercialization Partner for Its FGF-1 Protein Treatment for Cardiovascular Disease Patients

   "It's only a matter of time before the world at large comes to understand what The Bruckner Group has independently determined after lengthy investigation and analysis that overcame our initial skepticism," said David Balekdjian, Partner, The Bruckner Group. "Based on the currently-available data--which is more substantial than most third parties appreciate--The Bruckner Group believes that CVBT is on the path to developing the breakthrough angiogenic treatment for advanced CAD patients that has been long sought after," Balekdjian said. "If CVBT's protein therapy candidate CVBT-141H continues its clinical trial successes in growing new arteries to restore blood flow in the hearts of ischemic patients, without safety or side effect issues--and none have emerged in 69 patients dosed to date, CVBT-141H will revolutionize treatment of heart disease. Upon approval by regulators following successful conclusion of the clinical trials, projected levels of revenue generation for this and other ischemic indications would make CVBT the largest biotechnology company in the world," Balekdjian said.

   "The corporate development opportunity is clear," Balekdjian continued. "At a time when most major pharmaceutical manufacturers are struggling to grow revenues, are challenged by patent expirations, and face depleted pipelines, CVBT-141H offers revenue generation possibilities at levels rarely seen. The Bruckner Group believes that the CVBT-141H opportunity is, frankly, astonishing," Balekdjian said.

   Others have also taken note. BusinessWeek Online published "The Search for Angiogenesis" on July 6, 2007, which highlighted the promise of CVBT-141H, and in August 2007, Pharmaceutical Executive magazine named CVBT-141H one of the pharmaceutical industry's seven most important drugs in development.

   According to Daniel Montano, CVBT's CEO, "We're excited to be working with The Bruckner Group to find a commercialization partner for CVBT-141H. While CVBT had the option to engage many parties including investment bankers, we chose to instead work with BGI, for three key reasons. The Bruckner Group has an industry reputation for strategic and independent thought, meticulousness, and highly accurate predictions. It means something in the pharmaceutical and biotechnology industries when The Bruckner Group publicly takes a position," Montano said.

   "Additionally, The Bruckner Group, as the industry leader in healthcare value strategy, draws upon important pharma and biotech industry relationships, and substantial corporate development expertise," Daniel Montano indicated. "Furthermore, we believe that BGI's work on CVBT-141H's commercialization and healthcare value strategies will be important components of our discussions with potential partners. Assuming that the ongoing clinical trials are successful and CVBT-141H is ultimately approved by the FDA, we believe the key to CVBT's revenue maximization is implementation of a healthcare value strategy for CVBT-141H. In addition to addressing the clinical needs of patients and physicians, CVBT is seeking to address the healthcare value needs of payers by ensuring that our human FGF-1 product is cost-advantageous to use," Daniel Montano said.

   A 2007 Bruckner Group study indicated that use of CVBT-141H could reduce treatment costs of limited option CAD patients by 20% over a five-year period, inclusive of treatment cost. According to David Balekdjian, "Historically, treatment breakthroughs in any disease area add cost to the healthcare system. It's all but unheard of to have a potential treatment breakthrough like CVBT-141H that actually reduces costs substantially--and for the most expensive disease, cardiovascular disease. At a time when the healthcare system is straining to control spiraling costs, BGI believes that a breakthrough treatment that actually reduces treatment costs will be enormously successful."

   David Balekdjian indicated that BGI and CVBT are currently engaged in European commercialization discussions with several parties, and are seeking to expand the number of those discussions. "While there are very active discussions ongoing, they largely emerged informally rather than as a result of systematic CVBT efforts. CVBT's management believes the time has come to expand these discussions to all bona fide candidates, in order to best serve the interests of CVBT's shareholders. Based upon the significant level of interest that The Bruckner Group is already seeing and the advanced state of some of these discussions, BGI believes that a commercialization deal will be concluded in 2008."

   For more information about this opportunity, please contact David Balekdjian of The Bruckner Group at (781) 245-4454.

   Keywords: Angiogenesis, Angiology, Biopharmaceuticals, Biotechnology, Biotechnology Business, Biotechnology Company, Biotherapeutics, Cardiology, Cardiovascular Disease, Clinical Trial Research, Coronary Artery Disease, Drug Development, Genomics, Heart Disease, Oncology, Patent Actions, Patents Actions, Pharmaceuticals, Protein Therapies, Proteomics, Therapy, Treatment, Tumor Vascularization, The Bruckner Group.

   This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.

Return to Cardiovascular Business Alert Section